CryoPort’s Strong Performance and Growth Potential Justifies Buy Rating Despite Macroeconomic Challenges

BTIG analyst David Larsen has reiterated their bullish stance on CYRX stock, giving a Buy rating today.

David Larsen has given his Buy rating due to a combination of factors that highlight CryoPort’s strong performance and potential for growth. Despite concerns about macroeconomic challenges such as tariffs and drug pricing regulations, CryoPort reported a 10% year-over-year increase in total revenue for the first quarter of 2025, surpassing both BTIG and consensus estimates. The Life Sciences Services Division showed impressive growth with a 17% increase, and BioStorage revenue rose by 23%, indicating a robust demand in the cell and gene therapy sector.
Furthermore, CryoPort’s management has effectively managed cost structures, leading to a significant improvement in gross profit and margin expansion. The company has also demonstrated resilience by mitigating cost headwinds through strategic sourcing and passing on tariff-related costs to customers. With a positive outlook on revenue growth and the potential for EBITDA improvement throughout the year, Larsen sees CryoPort’s infrastructure investments translating into solid revenue growth, justifying the Buy rating.

Larsen covers the Healthcare sector, focusing on stocks such as DocGo, Healthequity, and Health Catalyst. According to TipRanks, Larsen has an average return of -11.0% and a 29.46% success rate on recommended stocks.

In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $15.00 price target.